OXFORD CANNABINOID TECHNOLOGIES HOLDINGS PLC

Oxford Cannabinoid Technologies Holdings Plc

Equities

OCTP

GB00BMVMRB86

Biotechnology & Medical Research

Market Closed - London S.E. Other stock markets 11:35:16 2024-05-17 am EDT			5-day change	1st Jan Change
0.155 ^GBX	0.00%		+3.33%	-75.20%

May. 17	Oxford Cannabinoid says it remains bound by Takeover Code	AN
May. 08	Oxford Cannabinoid shares plummet following delisting request	AN

Oxford Cannabinoid Technologies with "lots to look forward to" after interims

January 26, 2023 at 03:13 am EST

(via NewsDirect)

Oxford Cannabinoid Technologies Holdings PLC (LSE:OCTP, OTCQB:OCTHF) CEO Clarissa Sowemimo-Coker speaks to Proactive's Thomas Warner following the release of interim results for the six months ending 31st October 2022. Sowemimo-Coker looks ahead to what investors can expect during the first half, saying that there is "plenty to look forward to." She also reveals details of the current state of the company's finances.

Contact Details

Proactive UK Ltd

+44 20 7989 0813

uk@proactiveinvestors.com

Latest news about Oxford Cannabinoid Technologies Holdings Plc

Oxford Cannabinoid says it remains bound by Takeover Code	May. 17	AN
Oxford Cannabinoid shares plummet following delisting request	May. 08	AN
Oxford Cannabinoid Technologies Files for Delisting From London Bourse	May. 08	MT
Oxford Cannabinoid teams with iNGENu to test OCT130401 pain treatment	Apr. 11	AN
Oxford Cannabinoid Technologies Holdings plc Appoints Timothy Henry Corn as A Director	Apr. 08	CI
Oxford Cannabinoid Technologies Holdings plc Appoints Lord Darren James Mott as Director	Apr. 07	CI
Oxford Cannabinoid Technologies Holdings plc Appoints Lord Mott OBE as an Independent Non-Executive Director	Feb. 29	CI
Oxford Cannabinoid Technologies Holdings plc Announces Board Changes, Effective 31 March 2024	Feb. 29	CI
Oxford Cannabinoid completes capital reorganisation	Feb. 16	AN
Oxford Cannabinoid Technologies Concludes Capital Reorganization	Feb. 16	MT
Oxford Cannabinoid Technologies Completes Equity Raise	Feb. 15	MT
Oxford Cannabinoid shares up on applying to admit new shares	Feb. 15	AN
Oxford Cannabinoid applies for new shares to be listed	Feb. 14	AN
Oxford Cannabinoid Technologies Applies for Admission of Redenominated Shares on London Bourse	Feb. 14	MT
Oxford Cannabinoid Technologies Enters Convertible Loan Note Agreements	Feb. 02	MT
Oxford Cannabinoid agrees GBP565,000 loan notes deal	Feb. 02	AN
Oxford Cannabinoid Technologies to Raise GBP1.2 Million via Subscriptions, Investment; Shares Plunge	Jan. 30	MT
Oxford Cannabinoid Technologies down after GBP1.2 million fundraise	Jan. 30	AN
Oxford Cannabinoid Technologies Holdings Plc Reports Earnings Results for the Half Year Ended October 31, 2023	Jan. 30	CI
Oxford Cannabinoid Technologies Files Patent for New Cannabinoid Compound in Europe	Jan. 10	MT
Oxford Cannabinoid stock goes high on Europe patent filing	Jan. 10	AN
Oxford Cannabinoid Technologies Holdings plc Files A European Application in Own Name, Directed to Programme 2	Jan. 10	CI
Oxford Cannabinoid Technologies Holdings plc Appoints Tim Corn as an Executive Director	Nov. 14	CI
Kingsley Capital reduces stake in Oxford Cannabinoid	23-10-20	AN
Oxford Cannabinoid Technologies Completes Dosing in Phase 1 Study for Lead Drug Candidate	23-10-10	MT

Chart Oxford Cannabinoid Technologies Holdings Plc

Duration

Period

Chart Oxford Cannabinoid Technologies Holdings Plc

More charts

Company Profile

Oxford Cannabinoid Technologies Holdings plc is a United Kingdom-based pharmaceutical company developing prescription cannabinoid medicines. The Company is working with three types of cannabinoid compounds: synthesized phytocannabinoids, cannabinoid derivatives and novel chemical entities. Its drug development pipeline comprises both natural and synthetic compounds, and includes compounds targeting trigeminal neuralgia, a severe type of face pain, and cannabinoid derivatives targeting pain and other therapeutic areas. It has a portfolio of four drug development programs: Program 1 (OCT461201), Program 2 (OCT130401), Program 3 (Cannabinoid derivative) and Program 4 (Cannabinoid derivative). Its OCT461201 is a new chemical entity, CB2 receptor agonist, chemically synthesized to behave like a cannabinoid. Its OCT130401 is a drug/device combination. It has a portfolio of over 500 derivatives and intellectual property rights, including 14 patent families and associated research data.

Sector

Biotechnology & Medical Research

Calendar

2024-10-08 - Q4 2024 Earnings Release (Projected)

More about the company

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
OXFORD CANNABINOID TECHNOLOGIES HOLDINGS PLC	-75.20%	2.14M
MODERNA, INC.	+33.63%	50.85B
IQVIA HOLDINGS INC.	-0.09%	42.82B
LONZA GROUP AG	+49.62%	42.03B
CELLTRION, INC.	-4.96%	29.55B
ICON PUBLIC LIMITED COMPANY	+11.18%	26.11B
ALNYLAM PHARMACEUTICALS, INC.	-21.95%	19.13B
BIO-TECHNE CORPORATION	+8.61%	13.05B
MEDPACE HOLDINGS, INC.	+28.31%	12.16B
UNITED THERAPEUTICS CORPORATION	+24.73%	12.08B

Other Biotechnology & Medical Research

Oxford Cannabinoid Technologies Holdings Plc

Equities

OCTP

GB00BMVMRB86

Biotechnology & Medical Research

Oxford Cannabinoid Technologies with "lots to look forward to" after interims

Contact Details

Latest news about Oxford Cannabinoid Technologies Holdings Plc

Chart Oxford Cannabinoid Technologies Holdings Plc

Company Profile

Income Statement Evolution

EPS Revisions

Annual profits - Rate of surprise

Sector Other Biotechnology & Medical Research